Cepheid’s Post

In this case study video, Dr Andrew Armstrong takes us through the treatment of a patient with metastatic castration-resistant prostate cancer. 👉 https://ow.ly/JW9850QeX14 How should we treat this patient using PARP inhibitors in combination with non-hormonal agents? Dr Armstrong guides us through this patient's germline and somatic genetic assessment and how the outcome impacts our choice of therapy. We are led through the latest trial data regarding the efficacy and side-effects of PARP inhibitors and how to use this information to guide our treatment choices. This program is endorsed by ZERO Prostate Cancer and NASPCC #MedEd #ProstateCancer #MedicalEducation #Oncology

Genetic testing takes guess work out of breast cancer treatment ❔ Molecular sequencing pinpoints which triple-negative breast cancer patients need radiation, but it will take time before it’s easily accessible. https://lnkd.in/gxTGdfad #generalpractice #primarycare #familymedicine #breastcancer #oncology #genetics

In this case study treating mCRPC with PARP inhibitors + novel hormonal agents, Dr. Andrew Armstrong walks us through a patient's journey, highlighting the importance of genetic testing to guide treatment, efficacy and safety of PARP inhibitor combos, and personalizing therapy based on HRR status. Watch the video to learn how to optimize treatment for your mCRPC patients! 📺 Thank you to COR2ED and GU CONNECT for sharing this great content. #ZEROProstateCancer #ProstateCancer #PrecisionMedicine

Have you heard the news? The #IASLC and 23andMe are teaming up in the fight against #lungcancer. Participate in the Lung Cancer Genetics Study & help us unlock the potential of genetic insights for lung cancer. Learn more at https://lnkd.in/grZ2Pkbk #LCSM #LungCancer

Additional data supporting MammaPrint® utility in treatment selection will be presented in a #ASCO24 poster by other investigators titled “Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancer Closely Resembles Triple Negative Breast Cancer: Results from Gene Expression Data from the ISPY2 Trial” [Rios-Hoyo, A., et al.]. Attend the poster session presentation on June 2nd from 9:00am – 12:00pm CT. View the poster here: https://lnkd.in/gFYypyMQ #ASCO24 #oncology #breastcancer

There are some exciting insights from a recent interview with Dr. Alexandra Sokolova from Oregon Health & Science University, conducted by Andrea Miyahira of the Prostate Cancer Foundation. Dr. Sokolova’s team presented groundbreaking research on genomic alterations associated with responses to Lutetium PSMA (Pluvicto) in metastatic castration-resistant prostate cancer. They found that alterations in FGFR, MYC, and CDK12 genes are linked to lower PSA50 responses and that tumor suppressor gene alterations (TP53, RB1, PTEN) were associated with poorer overall survival and progression-free survival. This research has the potential to better predict patient response to Pluvicto and enhance personalized treatment strategies! See comments for the link to the interview. #ProstateCancer #CancerResearch #PrecisionMedicine #Radiotheranostics #Oncology

🧐Check out the #Article "Potential Impact of PI3K-AKT Signaling Pathway Genes, KLF-14, MDM4, miRNAs 27a, miRNA-196a Genetic Alterations in the Predisposition and Progression of Breast Cancer Patients" 👏by Othman R. Alzahrani et al. University of Tabuk 📌Find out more here: https://lnkd.in/d2MJnE9m Keywords: breast cancer; amplification refractory mutation system (ARMS); whole-exome sequencing (WES)

Analysis of Whole Genome Sequencing data on 10,478 cancer patients identifies 74 new drivers - Simona Cristea #Cancer #PancreaticCancer #OncoDaily #Oncology #WholeGenomeSequencing

🐾 New Study Saturday 🐾 Researchers at the University of Missouri-Columbia, funded by CHF, are investigating what mutations are driving the spread of oral malignant melanoma in dogs. By comparing genetic mutations between the primary mouth tumor and its spread to lymph nodes, they may identify new therapeutic targets for this highly metastatic cancer. 👀 Learn more about this important study at https://bit.ly/3Pvb47Q. #NewStudySaturday #OralMalignantMelanoma #CanineHealthResearch

Engaging patients is critical for advancing cancer research and a central tenet of the #CancerMoonshot initiative. A new Commentary in American Society of Clinical Oncology (ASCO)'s Journal of Clinical Oncology offers insights from the Participant Engagement & Cancer Genome Sequencing (PE-CGS) Network. The article explores structural barriers that have historically hindered participant involvement in research and proposes actionable solutions to overcome these obstacles. Read more here: https://bit.ly/PECGS-JCO